ReviewJournal of physiology and biochemistry2025
FXR crosstalk with other nuclear receptors.
Review in Journal of physiology and biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Integrated omics reveal the effects of vitamin D deficiency on gut microbiota and plasma metabolism in experimental autoimmune uveitis.Journal of neuroinflammation · 2026Article
- Emerging insights of bile acids in cardiovascular physiology and disease: from molecular mechanisms to therapeutic potential.Frontiers in pharmacology · 2026Review
- Gut Microbiota in the Regulation of Intestinal Drug Transporters: Molecular Mechanisms and Pharmacokinetic Implications.International journal of molecular sciences · 2025Review
- Article
- Bile acid-microbiota interactions in cardiometabolic diseases: mechanisms and emerging therapeutic approaches.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The farnesoid X receptor (FXR), a nuclear receptor (NR), plays a key role in balancing bile acid (BA), lipid, and glucose metabolism. By partnering with the retinoid X receptor (RXR), FXR influences gene transcription critical to these metabolic pathways. It also interacts with other NRs, including the pregnane X receptor (PXR), liver X receptor (LXR), and vitamin D receptor (VDR), creating an intricate signalling network. FXR activation triggers the production of small heterodimer partner (SHP), which suppresses cholesterol 7 alpha-hydroxylase (CYP7A1), the enzyme controlling BA synthesis. It also regulates lipid metabolism by controlling sterol regulatory element-binding protein 1c (SREBP-1c) and affects glucose balance. LXR, activated by oxysterols, supports reverse cholesterol transport (RCT) by regulating the expression of adenosine triphosphate binding cassette A1 (ABCA1) and adenosine-binding cassette sub-family G member 1 (ABCG1). Since FXR affects LXR-regulated genes, it indirectly modulates cholesterol homeostasis. Meanwhile, PXR, a xenobiotic sensor responsive to diverse compounds, such as BAs, regulates genes involved in drug detoxification and transport. FXR activation enhances PXR expression, influencing BA metabolism and removal. VDR, which responds to vitamin D and specific BAs such as lithocholic acid, plays a role in calcium balance and xenobiotic processing. The interplay among these NRs underscores FXR's central role in metabolic regulation and its potential as a therapeutic target for metabolic disorders.
Indexed as
Identifiers
40790373What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.